PFE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PFE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Pfizer's revenue for the three months ended in Jun. 2024 was $13,283 Mil. Its revenue for the trailing twelve months (TTM) ended in Jun. 2024 was $55,642 Mil. Pfizer's Revenue per Share for the three months ended in Jun. 2024 was $2.33. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2024 was $9.81.
Warning Sign:
Pfizer Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Pfizer was -28.30% per year. During the past 3 years, the average Revenue per Share Growth Rate was 11.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 16.70% per year. During the past 10 years, the average Revenue per Share Growth Rate was 5.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Pfizer's highest 3-Year average Revenue per Share Growth Rate was 34.40% per year. The lowest was -5.60% per year. And the median was 7.10% per year.
The historical data trend for Pfizer's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Revenue | Get a 7-Day Free Trial | 40,905.00 | 41,651.00 | 81,288.00 | 100,330.00 | 58,496.00 |
Pfizer Quarterly Data | ||||||||||||||||||||
Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | |
Revenue | Get a 7-Day Free Trial | 13,006.00 | 13,232.00 | 14,249.00 | 14,878.00 | 13,283.00 |
For the Drug Manufacturers - General subindustry, Pfizer's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Pfizer's Revenue distribution charts can be found below:
* The bar in red indicates where Pfizer's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $55,642 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pfizer (NYSE:PFE) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Thank you for viewing the detailed overview of Pfizer's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer B. Damico | officer: SVP & Controller | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Scott Gottlieb | director | MOLECULAR INSIGHT PHARMACEUTICALS, 160 SECOND STREET, CAMBRIDGE MA 02142 |
Christoffel Boshoff | officer: Executive Vice President | 66 HUDSON BOULEVARD EAST, NEW YORK NY 10001-2192 |
Payal Sahni | officer: Executive Vice President | ATTN: PFIZER CORP. SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
Carapezzi William R Jr | officer: Executive Vice President | 600 MOUNTAIN AVENUE, MURRAY HILL NJ 07921 |
Douglas M Lankler | officer: Senior Vice President | PFIZER INC. ATTN: CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Mikael Dolsten | officer: Senior Vice President | 5 GIRALDA FARMS, MADISON NJ 07940 |
David M Denton | officer: Chief Financial Officer & EVP | 1000 LOWE'S BOULEVARD, MOORESVILLE NC 28117 |
William Pao | officer: Executive Vice President | C/O CORPORATE SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Michael Mcdermott | officer: Executive Vice President | C/O PFIZER INC. CORPORATE SECRETARY, 235 EAST 42ND STREET, 235 EAST 42ND STREET NY 10017 |
Rady A Johnson | officer: Executive Vice President | PFIZER INC. ATTN CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Alexander R Mackenzie | officer: Executive Vice President | C/O PFIZER CORP. SECRETARY, 235 EAST 42ND STREET, NEW YORK NY 10017 |
Sally Susman | officer: Senior Vice President | 767 FIFTH AVE, EOTIC LAWDER CORP, NEW YORK NY 10153 |
Angela Hwang | officer: Group President | 235 EAST 42ND STREET, ATTN: CORPORATE SECRETARY, NEW YORK NY 10017 |
John D Young | officer: Business Unit President | C/O CORPORATE SECRETARY, 235 EAST 42ND ST., NEW YORK NY 10017 |
From GuruFocus
By Business Wire • 09-14-2024
By Business Wire • 09-20-2024
By Business Wire • 07-09-2024
By GuruFocus Research • 07-31-2024
By Business Wire • 08-16-2024
By Business Wire • 05-31-2024
By Nabeel Bukhari • 09-15-2024
By Business Wire • 09-25-2024
By Business Wire • 07-11-2024
By Business Wire • 08-12-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.